Wedbush reissued their buy rating on shares of Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR) in a research note published on Wednesday.
Other analysts have also recently issued research reports about the company. BTIG Research started coverage on Eiger BioPharmaceuticals in a report on Friday, July 14th. They issued a buy rating and a $32.00 price target for the company. Zacks Investment Research upgraded Eiger BioPharmaceuticals from a hold rating to a buy rating and set a $15.00 price target for the company in a report on Monday, October 16th. Oppenheimer Holdings, Inc. restated a buy rating and issued a $34.00 price target on shares of Eiger BioPharmaceuticals in a report on Monday, September 25th. Piper Jaffray Companies restated a buy rating and issued a $36.00 price target on shares of Eiger BioPharmaceuticals in a report on Tuesday, August 15th. Finally, Roth Capital started coverage on Eiger BioPharmaceuticals in a report on Thursday, October 19th. They issued a buy rating and a $35.00 price target for the company. One analyst has rated the stock with a sell rating, one has given a hold rating and six have issued a buy rating to the company. The stock has an average rating of Buy and a consensus price target of $30.43.
Shares of Eiger BioPharmaceuticals (NASDAQ:EIGR) traded down 1.830% during midday trading on Wednesday, hitting $10.995. 28,854 shares of the company were exchanged. The stock’s market capitalization is $92.00 million. Eiger BioPharmaceuticals has a 52-week low of $6.10 and a 52-week high of $13.95. The company has a 50-day moving average price of $11.48 and a 200-day moving average price of $8.78.
Eiger BioPharmaceuticals (NASDAQ:EIGR) last posted its quarterly earnings data on Monday, August 14th. The biotechnology company reported ($1.33) EPS for the quarter, missing analysts’ consensus estimates of ($1.28) by ($0.05). On average, analysts forecast that Eiger BioPharmaceuticals will post ($5.20) EPS for the current year.
In other Eiger BioPharmaceuticals news, Director Jeffrey S. Glenn purchased 15,000 shares of the stock in a transaction on Friday, September 1st. The stock was bought at an average price of $9.53 per share, for a total transaction of $142,950.00. Following the acquisition, the director now directly owns 31,355 shares of the company’s stock, valued at $298,813.15. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. 28.80% of the stock is owned by insiders.
A number of institutional investors and hedge funds have recently bought and sold shares of EIGR. Bank of New York Mellon Corp grew its holdings in Eiger BioPharmaceuticals by 4.7% in the 1st quarter. Bank of New York Mellon Corp now owns 13,696 shares of the biotechnology company’s stock valued at $157,000 after buying an additional 614 shares during the period. LMR Partners LLP purchased a new stake in Eiger BioPharmaceuticals in the 2nd quarter valued at about $116,000. Hikari Power Ltd grew its holdings in Eiger BioPharmaceuticals by 491.0% in the 2nd quarter. Hikari Power Ltd now owns 60,992 shares of the biotechnology company’s stock valued at $482,000 after buying an additional 50,672 shares during the period. Goldman Sachs Group Inc. purchased a new stake in Eiger BioPharmaceuticals in the 2nd quarter valued at about $272,000. Finally, Susquehanna International Group LLP purchased a new stake in shares of Eiger BioPharmaceuticals during the 2nd quarter worth about $114,000. Institutional investors own 59.94% of the company’s stock.
About Eiger BioPharmaceuticals
Eiger BioPharmaceuticals, Inc, formerly Celladon Corporation, is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of products for the treatment of orphan diseases. Its pipeline includes Sarasar (lonafarnib) for hepatitis delta virus (HDV), exendin (9-39) for severe hypoglycemia, and Bestatin (ubenimex) for pulmonary arterial hypertension (PAH) and lymphedema.